AlphAIAlphAI — Financial news for AI agents
investing.comNOV 31 min read$DNLI

Denali Therapeutics soars on earnings beat

Denali Therapeutics (DNLI) reported Q3 earnings beating estimates, with adjusted EPS of $0.37 vs. -$0.37 expected. Revenue was $17.77M, surpassing the $12.22M estimate. AVLAYAH sales drove growth, with net product revenue of $17.8M. The company guided Q4 2026 net product revenue to $30.0M-$32.0M. DNLI shares rose 9.8% in after-hours trading.

Original reporting
investing.com
Published Nov 3, 2026, 9:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DNLI
Bullish
high confidence
Mentioned
$DNLI
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DNLIBullishHigh
01

Why it matters

The earnings surprise and guidance raise expectations for the company's pipeline, especially the newly launched AVLAYAH for Hunter syndrome.

02

Market read

Earnings beat and strong product uptake could trigger a short‑term rally in DNLI and positively influence peer biotech stocks.

03

What to watch

High R&D spend and cash burn could pressure the stock if future sales do not scale.

Relevance 7/10Novelty 8/10Timing: after‑hours today

Background

Denali Therapeutics (NASDAQ:DNLI) is a biotech company developing treatments for rare neurodegenerative diseases.

Company-level read

Ticker impact

$DNLIBullishHigh confidence
Context

Denali Therapeutics reported Q3 earnings beat and a 9.8% after‑hours price jump.

Expected impact

likely upward pressure as traders price in better-than-expected earnings and guidance.

Evidence & confidence

The company posted adjusted EPS of $0.37 versus a consensus of -$0.37 and revenue beat, plus guidance above prior expectations, which typically supports a rally.

Market effects

Sector

Positive signal for biotech firms with recent FDA approvals, may lift sector sentiment.

Regional

U.S. biotech market may see modest gains.

Global

Limited to investors focused on U.S. biotech and rare‑disease therapeutics.

Counterpoint

What could challenge this read

The earnings beat is driven by a one‑time voucher sale; core product revenue remains modest.

Key entities

  • company
    Denali Therapeutics

    Biotech firm reporting earnings.

  • product
    AVLAYAH

    FDA‑approved therapy for Hunter syndrome.

Read at source← All news

StoryDenali Therapeutics reports Q3 earnings beat and raises Q4 AVLAYAH revenue outlook

Also covered by

2 outlets

Related articles

NOV 4
$DNLIMed

Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars

Denali Therapeutics (DNLI) reported Q3 2026 revenue of $17.8M, exceeding guidance, and raised Q4 outlook to $30-32M. Growth was driven by payer coverage and patient transitions. The company expects a permanent J-Code to aid Q4 revenue. CEO Ryan Watts discussed regulatory paths for FTD and Pompe programs, and CFO Alexander Schuth mentioned $1B in cash for advancements. AVLAYAH's price is $5,200 per vial, with no reported discontinuations.

finance.yahoo.com3 min
NOV 4
$DNLIHighAI 8/10

Why is Denali Therapeutics stock surging today?

Denali Therapeutics (DNLI) stock rose 7.9% in pre-market trading after Q3 2026 earnings beat estimates, with revenue of $17.77M and EPS of $0.37. AVLAYAH, its therapy for neurologic Hunter syndrome, drove growth, with revenue up 394% QoQ. Management guided Q4 revenue to $30M-$32M. Analysts raised price targets, with a consensus of $35.85. U.S. equity futures also rallied post-election.

investing.com2 min
NOV 4
$DNLIHighAI 8/10

Denali Therapeutics Q3 Earnings Call Highlights

Denali Therapeutics reported Q3 revenue growth due to expanded coverage and patient transitions. AVLAYAH's J-code became effective, simplifying billing. Revenue is expected to rise steadily. Sanfilippo syndrome type A trial data to be presented in 2027. Alzheimer's programs in clinical trials. Q3 net income was $70.1M, with $1.01B in cash. Company aims to build two commercial brands and advance multiple programs by 2028.

finance.yahoo.com3 min
NOV 3
$DNLIMed

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights • AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter • Continued growth expectations drive Q4 2026 net produ

SEC EDGAR 8-K2 min
AUG 13
$DNLIMedAI 8/10

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics (DNLI) reported Q2 2026 net product revenue of $3.6 million from the first full quarter of AVLAYAH in the US. It guided Q3 revenue to $10 million to $12 million and said pro forma cash and securities were $1.1 billion after a $195 million priority review voucher sale. R&D was $97.0 million; net loss was $127.6 million.

fool.com6 min